Fourth, in the subgroup analysis comparing DPP-4 inhibitors with SGLT-2 inhibitors, we observed an implausibly wide CI for HF risk (OR = 2.46; 95% CI, 0.24–24.73). The gene discussed is DPP4; the disease is hydrops fetalis.